Related Experiment Video
Updated: Jun 18, 2026

Fibroblast Derived Human Engineered Connective Tissue for Screening Applications
Published on: August 20, 2021
Fibroblast growth factor 21: from pharmacology to physiology
Steven A Kliewer1, David J Mangelsdorf
1Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 73590-9041, USA. steven.kliewer@utsouthwestern.edu
Abstract:
Fibroblast growth factor 21 (FGF21) is an atypical member of the FGF family that functions as an endocrine hormone. Pharmacologic studies show that FGF21 has broad metabolic actions in obese rodents and primates that include enhancing insulin sensitivity, decreasing triglyceride concentrations, and causing weight loss. In lean rodents, FGF21 expression is strongly induced in liver by prolonged fasting through a mechanism that involves the nuclear receptor peroxisome proliferator-activated receptor alpha. FGF21, in turn, induces the transcriptional coactivator protein peroxisome proliferator-activated receptor gamma coactivator protein 1alpha and stimulates hepatic gluconeogenesis, fatty acid oxidation, and ketogenesis. FGF21 also blocks somatic growth and sensitizes mice to a hibernation-like state of torpor. Thus, FGF21 plays a key role in eliciting and coordinating the adaptive starvation response. Interestingly, FGF21 expression is induced in white adipose tissue by peroxisome proliferator-activated receptor gamma, which suggests that it also regulates metabolism in the fed state. This article highlights recent advances in our understanding of FGF21's pharmacologic and physiologic actions.
Insights
Fibroblast growth factor 21 (FGF21) is an endocrine hormone with significant metabolic actions. It enhances insulin sensitivity, reduces triglycerides, and promotes weight loss, playing a key role in the body's starvation response.
Area of Science:
- Endocrinology
- Metabolic Regulation
- Molecular Biology
Background:
- Fibroblast growth factor 21 (FGF21) is an atypical endocrine hormone within the FGF family.
- Pharmacologic studies indicate FGF21 possesses broad metabolic effects in obese animals, including improved insulin sensitivity, reduced triglycerides, and weight loss.
Purpose of the Study:
- To highlight recent advances in understanding the pharmacologic and physiologic actions of FGF21.
- To elucidate FGF21's role in metabolic regulation during fasting and fed states.
Main Methods:
- Review of pharmacologic studies on FGF21's metabolic effects in rodents and primates.
- Analysis of FGF21 induction mechanisms during fasting in lean rodents involving PPARα.
- Investigation of FGF21's role in hepatic gluconeogenesis, fatty acid oxidation, and ketogenesis.
Main Results:
- FGF21 expression is induced by prolonged fasting in the liver via peroxisome proliferator-activated receptor alpha (PPARα).
- FGF21 stimulates hepatic gluconeogenesis, fatty acid oxidation, and ketogenesis, while also inducing PGC-1α.
- FGF21 expression in adipose tissue is induced by peroxisome proliferator-activated receptor gamma (PPARγ), suggesting a role in fed-state metabolism.
Conclusions:
- FGF21 is a critical regulator of the adaptive starvation response, coordinating metabolic adjustments.
- FGF21 exhibits significant therapeutic potential for metabolic disorders like obesity and insulin resistance.
- Further research into FGF21's dual role in fasting and fed states is warranted.
Related Concept Videos
Introduction to Fibroblasts
Regulation of Angiogenesis and Blood Supply
TGF - β Signaling Pathway
Healing I: Introduction
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
